SGLT2 inhibitor study for older adults
Part of Heart & circulation, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how a class of diabetes and kidney drugs called SGLT2 inhibitors affect older adults. It aims to understand the benefits for your kidneys and metabolism.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years old or older.
- You have not started taking a medication called an SGLT2 inhibitor (like dapagliflozin or empagliflozin) yet.
- Your doctor has prescribed an SGLT2 inhibitor for you as part of your regular care.
- You are willing and able to sign a consent form and are also enrolled in two other studies (MED-Cli and MED-Mol).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a type of diabetes medicine called SGLT2 inhibitors (also known as flozins) can help protect the heart and kidneys in people with both heart failure with preserved pumping function and moderate chronic kidney disease, with or without diabetes.
This study looks at how SGLT2 inhibitors (a type of diabetes medication) protect the kidneys in people with type 2 diabetes and kidney disease. It may help explain why these drugs are beneficial for kidney health.
This trial tests whether a combination of two diabetes medicines, henagliflozin and metformin, can improve body composition (fat and muscle) in older adults new to diabetes treatment. It may help you better manage blood sugar and body weight.
This study tests whether a medicine called an SGLT2 inhibitor (a type of diabetes drug also used for heart failure) affects the heart and blood vessels in people with kidney failure who are on dialysis. It will help doctors understand if this medicine is safe and helpful for dialysis patients.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
This study tests how a drug called canagliflozin (an SGLT2 inhibitor) affects kidney function in people with type 2 diabetes. It involves two kidney biopsies to see how the drug works inside your kidneys, aiming to better protect kidney health.
Hear when a new Elderly Patients (>65 Years) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.